
No Data Available
|
Avexa Limited (AVX)
is a publicly listed company on the Australian Securities Exchange (ASX).
Company Announcements
No Company Announcements
General Overview
About Avexa Limited
Avexa Limited (ASX: AVX) is an Australian Medical Technology Company listed on the Australian Securities Exchange. Avexa’s core focus is the development of TALI Health and the TALI Technology. TALI Health is based in Melbourne and is made up of a team of neuroscientists, engineers, game developers and all-round talented individuals. Our vision is to be a leader in the assessment and treatment of childhood attention difficulties.
Services
Avexa Technology
What is TALI?
TALI is a scientifically validated computerised program for improving and profiling childhood attention difficulties. TALI presents as a series of game based exercises which harness cognitive training to enhance attention skills, such as the ability to attend to relevant information, filter out distractors and inhibit impulsive responding. The exercises adapt in real time to the gameplay of the child and key parameters can be tailored by the clinician. This approach means that the TALI program addresses the unique needs of each child.
TALI is used under licence through clinicians. The TALI System provides in depth analysis for clinicians and parents to highlight individual strengths and weaknesses in attention. The back end of the TALI System is a powerful computer program that collects and analyses data each time a child plays one of the training exercises. The analysis of this data is used to prepare reports for clinicians to use for therapeutic purposes, to monitor the progress of their client, and, where necessary, adjust the treatment.
The TALI Technology is portable and can be used at home or school. This makes it accessible to children in metropolitan and rural regions, particularly areas that often cannot access intervention services which are located predominantly in metropolitan regions.
Unlike other technology, the TALI Technology recognises that not all children will have the same degree or type of attention difficulty. In some children, the ability to remain focused on a given task may be especially weak but other attention skills, such as selection of salient information may be less vulnerable to impairment. These relative strengths, once identified, can be used to improve and build weaker attention skills and also improve cognitive functions related to working memory, literacy and numeracy.
By avoiding a “one-size-fits all” approach to early intervention the TALI Technology enables tailored treatment uniquely designed for each child.
Who needs TALI?
TALI is suitable for any child with attention difficulties. TALI is particularly beneficial for children who are at risk of attention difficulties due to an underlying developmental disability, such as autism spectrum disorder. TALI can make a huge difference to a child who is struggling to attend at home or in the classroom.
Price History
52 Week High | Change from 52 Week High | % Change from 52 Week High | 52 Week Low | Change from 52 Week Low | % Change from 52 Week Low |
---|---|---|---|---|---|
${{quote["Year's High"]}} | ${{(quote["Historic Close"] - quote["Year's High"]) | setDecimalCheckForNa}} | {{(((quote["Historic Close"] / quote["Year's High"]) - 1) * 100) | setDecimalCheckForNa}}% | ${{quote["Year's Low"] | setDecimalCheckForNa}} | ${{(quote["Historic Close"] - quote["Year's Low"])| setDecimalCheckForNa}} | {{(((quote["Historic Close"] / quote["Year's Low"]) - 1) * 100) | setDecimalCheckForNa}}% |
Upcoming Dividends
Organization Details | RIC | Dividend Amount | Ex Dividend Date | Dividend Payment Date | Yield | Franking % | Earnings | Current Price |
---|---|---|---|---|---|---|---|---|
{{UpcomingDividends[0]['Display Name']}} | {{UpcomingDividends[0].RIC}} | {{UpcomingDividends[0].Dividend}} | {{UpcomingDividends[0]['Ex-Dividend Date']}} | {{UpcomingDividends[0]['Dividend Date']}} | {{UpcomingDividends[0]['Yield']}} | {{UpcomingDividends[0]['GEN VAL2']}} | {{UpcomingDividends[0].Earnings}} | {{UpcomingDividends[0]['CF Last Price']}} |
The next upcoming dividend date has not yet been announced - Please watch this place for updated dividend information |
Historical Dividends
Dividend Yield | Dividend Yield (5 Yr Avg) | ISIN | Stock Code (RIC) | SEDOL | Dividend Currency |
---|---|---|---|---|---|
{{ratios.Valuation.DivYield_CurTTM.Value | setDecimalCheckForNa}} | {{ratios.Valuation.YLD5YAVG.Value | setDecimalCheckForNa}} | {{Dividends[0].ISIN}} | {{Dividends[0].RIC}} | {{Dividends[0].SEDOL}} | {{Dividends[0].DividendCurrency != '' ? Dividends[0].DividendCurrency : '-'}} |
Year | CorpActID | DPTD | DivAnnDate | DivExDate | DivPayDate | DTMD | DivRate | DRD | DRPrice | DTMD | DTMD | Frank% |
---|---|---|---|---|---|---|---|---|---|---|---|---|
{{item.DividendExDate == '01/01/1900' ? '-' : item.DividendExDate| date : 'dd/MM/yyyy'}} | {{item.CorporateActionsID}} | {{item.DividendPaymentTypeDescription}} | {{item.DividendAnnoucementDate == '00/01/1900' ? '-' : item.DividendAnnoucementDate| date : 'dd/MM/yyyy'}} | {{item.DividendExDate == '01/01/1900' ? '-' : item.DividendExDate| date : 'dd/MM/yyyy'}} | {{item.DividendPayDate == '01/01/1900' ? '-' : item.DividendPayDate| date : 'dd/MM/yyyy'}} | {{item.DividendTypeMarkerDescription}} | {{item.DividendRate != '0' ? item.DividendRate : '-'}} | {{item.DividendReinvestmentDeadline == '01/01/1900' ? '-' : item.DividendReinvestmentDeadline| date : 'dd/MM/yyyy'}} | {{item.DividendReinvestmentPrice != '0' ? item.DividendReinvestmentPrice : '-'}} | {{item.DividendTaxMarkerDescription != '' ? item.DividendTaxMarkerDescription : '-'}} | {{item.DividendTaxRate != '0' ? item.DividendTaxRate :'-'}} | {{item.FrankingPercent != '0' ? item.FrankingPercent : '-'}} |
Financial Reports
Financial Summary
Last Updated: {{generalInfo.TextInfo['Financial Summary'].LastUpdated}}
{{generalInfo.TextInfo['Financial Summary'].Value && generalInfo.TextInfo['Financial Summary'].Value != ''? generalInfo.TextInfo['Financial Summary'].Value: 'No Financial Summary Found.'}}
Accounting Notes
Fiscal Year Ends | Most Recent Quarter | Transfer agent | Auditor | Shariah Compliant |
---|---|---|---|---|
{{generalInfo.CompanyGeneralInfo.TotalSharesOut.Data | date:'dd/MM/yyyy' }} - |
- | - | {{generalInfo.Auditor && generalInfo.Auditor != ''? generalInfo.Auditor : '-'}} |
Fiscal Period | |
Period End Date: | |
Period Length | |
Ratios | Value |
Analyst Footnotes
Last Updated: {{generalInfo.TextInfo['Analyst Footnotes'].LastUpdated}}
{{generalInfo.TextInfo['Analyst Footnotes'].Value && generalInfo.TextInfo['Analyst Footnotes'].Value != '' ? generalInfo.TextInfo['Analyst Footnotes'].Value : 'No Analyst Footnotes Found.'}}
Directors, Officers & Company Executives
Start Date | End Date | |
---|---|---|
{{personobject.PersonInformation.Name.Info| getDirectorFullNameIncludingPrefix}} | ||
{{persontitlesobject.Value}}, | {{persontitles.Start.Day}}-{{persontitles.Start.Month}}-{{persontitles.Start.Year}} | {{persontitles.End.Day}}-{{persontitles.End.Month}}-{{persontitles.End.Year}} |
No Directors, Officers & Company Executives Information Found. |
Recommendation Statistics
No Recommendation Statistics
Recommendation Statistics | ||
---|---|---|
Recommendation | Number Of Analysts | |
Sell Reduce Hold Buy Strong Buy | {{stats.NumberOfAnalysts}} |
I/B/E/S Mean | ||
---|---|---|
{{verdict[meanmarker]}} | {{analystvotes}} Analysts | Mean recommendation from all analysts covering the company on a standardized 5-point scale. |
|
Past Broker Recommendations
No Past Recommendations
Past Broker Recommendations | ||||||
---|---|---|---|---|---|---|
Sell | Underperform | Hold | Buy | Strong Buy | Total | |
{{snapshots.Age === 1 ? "1 Week Ago" : (snapshots.Age === 2 ? "30 Days Ago" : (snapshots.Age === 3 ? "60 Days Ago" : (snapshots.Age === 4 ? "90 Days Ago" : "")))}} | {{snapshots.Statistics[0].NumberOfAnalysts}} | {{snapshots.Statistics[1].NumberOfAnalysts}} | {{snapshots.Statistics[2].NumberOfAnalysts}} | {{snapshots.Statistics[3].NumberOfAnalysts}} | {{snapshots.Statistics[4].NumberOfAnalysts}} | {{snapshots.NumberOfRecommendations}} |
Target Price
No Target Price
Target Price | |
---|---|
Mean | {{priceTarget.Mean}} |
High | {{priceTarget.High}} |
Low | {{priceTarget.Low}} |
Median | {{priceTarget.Median}} |
Standard Devitation | {{priceTarget.StandardDeviation}} |
Number Of Estimates | {{priceTarget.NumberOfEstimates}} |
Videos
No Videos Found
{{video.summary}}
Company Reports
No Company Reports
Website Links
Contact Info
Avexa Limited
Suite 8, Level 1
61-63 Camberwell Road
Hawthorn East,
VIC
Australia, 3123
Phone:
+61 3 8888 1040
Fax:
+61 3 8888 1049
Email:
reception@avexa.com.au
Website:
http://www.avexa.com.au